Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: jbershad who wrote (127)	1/5/1998 2:00:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 550

Jerry: >>You have understanding way beyond my simple knowledge of physical chemistry.<< It is only my best guess. Because I was bit surprised by SU101 cancer data coming solely from PDGF-R activity inhibitor. As you know, leflunomide is at the end of Phase III for RA, by Hoechst. Leflunomide has several bio-chemical activity: 1) reduction of the Pyrimidine NTP level (inhibition of the pyrimidine nuscleotide synthesis, suppress T-cells proliferation by DNA synthesis control), 2) inhibition of the src-family tyrosine kinase activity (grow factor receptors family tyrosine kinase: EGF-R, PDGF-R, VEGF-R Flt/KDR,..), 3) inhibition of the dihydroorotate dehydrogenase (immunomodulatory activity), 4) prostaglandin endoperoxide H synthase (inhibition of the Prostaglandin E2 synthesis, anti-inflammatory),... So, I can't say that I understand what is going on with SU101. However, I think that all this development are positive for SUGN and their anti-cancer drugs SU101 and SU5416. mz